Illuminating Advances in the Pharmacological Treatment of Dravet Syndrome

rare_disease_orphan_drug_big

By Dr Nicola Davies

For Dravet Syndrome Awareness Month (June), we explore advances in pharmacological treatments for this rare, drug-resistant epilepsy that is characterized by prolonged seizures and fevers that affect one side of the body.1

The worldwide prevalence of Dravet Syndrome (DS) is estimated to be 1:15,000-45,000, with the first symptoms often appearing in the first year of life.1 In the USA, DS affects 1 in 15,700 individuals – that’s about 0.0064% of the population.2 Approximately 80%-90% of those individuals have a mutation on the SCN1A gene and have been clinically diagnosed with DS.2 Different types of mutations – missense, deletion, frameshift – have been associated with the condition, and 90% of the mutations in children are not inherited from a parent.1,2 Children with DS often present with progressive cognitive impairment, with 86% of patients showing signs of intellectual deficiency and autism spectrum disorder being diagnosed in 31% of cases.1

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical